Blogs
Patient Centricity in HTA: Fact or Fable?
By Erfan Akbraian, Analyst Email: [email protected] In recent years there have been discussions to shift to a multi-stakeholder approach and increase early communication amongst key
Will the latest changes of the Bulgarian pricing and reimbursement policy have finally an impact?
By Akshay Kumar, Partner & Andrea Bernardini, Analyst Email: [email protected] [email protected] Bulgaria introduced multiple reforms to their healthcare system since 2011. This included the introduction of
France’s New ATU Process: Why only truly innovative therapies should now apply
By Nicola Allen, Associate Director & Andrea Bernardini, Analyst Email: [email protected] or [email protected] The French Authorisation for Temporary Use (ATU) was originally established in 1994
India’s new draft national policy for rare disease and the road to accessing gene therapies
By Ciaran Cassidy, Snr Analyst Email: [email protected] With one of the fastest-growing economies and the second largest population in the world India is a market
4 key trends changing the access landscape through to 2025
By Jens Leutloff, Senior Consultant Email: [email protected] Partners4Access asked payer experts from France, Germany, Italy, Spain, and the Nordics what the key trends are for
HTA and pricing update: Recent moves on drug cost-control by European payers
By Chloe Sheppard, Analyst Email: [email protected] The issue of affordability and access to medicines has been brought to the forefront of policymakers’ and payers’ attention
Trump finally signs executive order on Medicare drug pricing but will anything change on the ground?
By Max Rex, Consultant Email: [email protected] After years of rhetoric about drug pricing, President Trump signed an executive order on Sunday 13th September which aims
Driving patient access for treatments targeting rare genetic disorders in the Middle East
By Ciaran Cassidy, S Analyst Email: [email protected] At the World Orphan Drug Conference (WODC) this year Dr Maryam Matar presented on the success of the
Under the microscope: Orphan Drug incentives in Europe
By Chloe Sheppard, Analyst Email: [email protected] The European Commission is imminently expected to publish a report evaluating the pros and cons of the EU Orphan
